Skip to main content

Market Overview

BWXT Medical, Bayer AG Ink Agreement On Actinium-225

BWXT Medical, Bayer AG Ink Agreement On Actinium-225
  • BWX Technologies Inc's (NYSE: BWXT) subsidiary BWXT Medical Ltdhas agreed with Bayer AG (OTC: BAYRY) to develop Actinium-225 (Ac-225) supply and further partnering opportunities on finished products. The financial terms of the agreement were not disclosed.
  • The companies to broaden their respective commercialization strategies for targeted radionuclide therapies (TRTs) and other products.
  • Ac-225 is a radioisotope used in targeted alpha therapies (TATs), an emerging class of radionuclide therapy for various tumors with a high unmet medical need.
  • Bayer's oncology franchise includes six marketed products, including Xofigo and several other TATs in different stages of development.
  • The parties plan to finalize the terms of the commercial agreements at a later date.
  • Price Action: BWXT shares traded higher by 1.97% at $55.79 on the last check Thursday.

Related Articles (BWXT)

View Comments and Join the Discussion!

Posted-In: Briefs tumorsBiotech News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at